Immunotherapy Drugs Market

April 2019 | 104 pages | ID: I660F199933EN
IHR Insights

Abstracts

Global Immunotherapy Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025

[104 pages report] This market research report includes a detailed segmentation of the global immunotherapy drugs market by drug type (monoclonal antibodies, vaccine, non-specific immunotherapies, adaptive cell therapy, and others), by treatment area (cancer, inflammatory and autoimmune disease, infectious disease, and others), by regions (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global Immunotherapy Drugs Market

Infoholic’s market research report predicts that the “Global Immunotherapy Drugs Market” will grow at a CAGR of 12.5% during the forecast period. The market has witnessed steady growth in the past few years, and the introduction of novel products has increased the acceptance of immunotherapy drugs in the market. The market is fueled by an upsurge in the incidence of lifestyle and chronic disease globally, reduction in disease recurrence, increasing product approval, and high preference for immunotherapy over traditional chemotherapy.

The growing market trend continues and is becoming one of the increasingly accepted treatments across many countries worldwide. The manufacturers are focusing on new approvals, collaboration, and development of new products due to the increase in demand for immunotherapy drugs for the treatment of cancer and other diseases. Most of the revenue is generated from the leading players in the market with dominant sales such as AbbVie, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Johnson and Johnson, and Merck & Co., Inc.

According to Infoholic Research analysis, North America accounted for the largest share of the global immunotherapy drugs market in 2018. The US dominates the market owing to the presence of most of the immunotherapy drugs manufacturers in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period, owing to factors such as growing incidence of lifestyle diseases, increasing adoption of novel treatment, and low manufacturing cost.

By Drug Type:

• Monoclonal Antibodies (mAbs)
• Vaccines
• Non-specific Immunotherapies
• Adaptive Cell Therapy
• Others

The monoclonal antibodies segment occupied the largest share in 2018 and is expected to grow at low-double-digit CAGR during the forecast period. The adaptive cell therapy segment is expected to grow at a high CAGR during the forecast period 2019–2025.

By Treatment Area:

• Cancer
• Inflammation and Autoimmune Disease
• Infectious Disease
• Others

In 2018, the cancer segment occupied the largest share and is expected to grow at a high CAGR during the forecast period due to the rising incidence of cancer globally and increasing preference for immunotherapy as a first line of treatment.

By Regions:

• North America
• Europe
• APAC
• RoW

North America is dominant in the global immunotherapy drugs market, followed by Europe and Asia Pacific. The significant share of the North America market comes from the US due to the availability of favorable reimbursement policies.

Immunotherapy Drugs Market Research Competitive Analysis – The global immunotherapy drugs market has massive growth opportunities in both developed and developing regions. The introduction of a novel product with affordable drug cost is expected to increase the competition among the market players.

Many companies are currently focused on approvals, collaboration, and development of new products related to immunotherapy drugs due to increased demand for this therapy to treat various disease types.

For instance, in January 2019, BioNTech AG inked a deal with MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. The acquisition helps to expand BioNTech, which is a top privately-held developer of RNA-based therapeutics, further into monoclonal antibody (mAb) development to develop new treatments that combine technologies of both the companies. In June 2018, Novartis received European approval for Aimovig, for the prevention of migraine in adults, and it works by blocking the activity of calcitonin gene-related peptide (CGRP) that is involved in migraine attacks. It is the only treatment specifically designed for migraine prevention to be approved in the European Union. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new products to obtain a high share in the market.

Key Vendors:

• AbbVie, Inc.
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol–Myers Squibb
• Johnson and Johnson
• Merck & Co., Inc.

Key Competitive Facts

• Increasing disease incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the immunotherapy drug development are the major factors driving the market growth.
• With more than 8,000 ongoing trials for cancer immunotherapy, a huge amount of study concentrated on checkpoint inhibitors (CPi) and combinations with chemotherapies, targeted therapies, and other immune-oncology (IO) agents.

Benefits – The report provides complete details about the related sub-segments of the immunotherapy drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pure-play companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:

• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of the immunotherapy drugs industry.
• Factors influencing the growth of the immunotherapy drugs market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the immunotherapy drugs market in both developed and developing regions.
• Key insights related to major segments of the immunotherapy drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.

Contents

1 INDUSTRY OUTLOOK

1.1 Industry Overview
  1.1.1 Global Driver for Pharmaceutical Demand
  1.1.2 R&D Pipeline in Pharmaceutical Industry
  1.1.3 Top Pharma Drugs by Sales (In $Million)
1.2 Industry Trends

2 REPORT OUTLINE

2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 MARKET SNAPSHOT

3.1 Market Definition – Infoholic Research
3.2 Benefits of Immunotherapy
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the Immunotherapy Drugs Market
3.5 Related Markets
  3.5.1 Human Insulin
  3.5.2 Oncology Drugs

4 MARKET OUTLOOK

4.1 List of Cancer Immunotherapy Drugs Approved (2016- April 2019)
4.2 Market segmentation
4.3 PEST Analysis
4.4 Porter 5 (Five) Forces

5 MARKET CHARACTERISTICS

5.1 DRO – Global Immunotherapy Drugs Market Dynamics
  5.1.1 Drivers
    5.1.1.1 High preference of immunotherapy over traditional chemotherapy
    5.1.1.2 Growing incidence of lifestyle and chronic diseases
  5.1.2 Opportunities
    5.1.2.1 Emergence of biosimilars
    5.1.2.2 Increasing opportunities in the emerging market
  5.1.3 Restraints
    5.1.3.1 High immunotherapy treatment costs
    5.1.3.2 Complex manufacturing process
5.2 DRO – Impact Analysis
5.3 Key Stakeholders

6 DRUG TYPE: MARKET SIZE AND ANALYSIS

6.1 Overview
6.2 Monoclonal Antibodies (mAbs)
6.3 Vaccine
6.4 Non-specific Immunotherapy
6.5 Adaptive Cell Therapy
6.6 Others

7 TREATMENT AREA: MARKET SIZE AND ANALYSIS

7.1 Overview
7.2 Cancer
7.3 Inflammatory and Autoimmune Diseases
7.4 Infectious Disease
7.5 Others

8 REGIONS: MARKET SIZE AND ANALYSIS

8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World

9 COMPETITIVE LANDSCAPE

9.1 Overview

10 VENDOR PROFILES

10.1 AbbVie, Inc.
  10.1.1 Overview
  10.1.2 Geographic Revenue
  10.1.3 Business Focus
  10.1.4 SWOT Analysis
  10.1.5 Business Strategies
10.2 Amgen, Inc.
  10.2.1 Overview
  10.2.2 Geographic Revenue
  10.2.3 Business Focus
  10.2.4 SWOT Analysis
  10.2.5 Business Strategies
10.3 F. Hoffmann-La Roche Ltd.
  10.3.1 Overview
  10.3.2 Business Units
  10.3.3 Geographic Revenue
  10.3.4 Business Focus
  10.3.5 SWOT Analysis
  10.3.6 Business Strategies
10.4 Bristol-Myers Squibb
  10.4.1 Overview
  10.4.2 Geographic Revenue
  10.4.3 Business Focus
  10.4.4 SWOT Analysis
  10.4.5 Business Strategy
10.5 Johnson & Johnson
  10.5.1 Overview
  10.5.2 Business Units
  10.5.3 Geographic Revenue
  10.5.4 Business Focus
  10.5.5 SWOT Analysis
  10.5.6 Business Strategies
10.6 Merck & Co., Inc.
  10.6.1 Overview
  10.6.2 Business Units
  10.6.3 Geographic Revenue
  10.6.4 Business Focus
  10.6.5 SWOT Analysis
  10.6.6 Business Strategies

11 COMPANIES TO WATCH FOR

11.1 Novartis AG
  11.1.1 Overview
11.2 GlaxoSmithKline plc
  11.2.1 Overview
11.3 AstraZeneca PLC
  11.3.1 Overview
11.4 Eli Lilly and Company Ltd
  11.4.1 Overview

12 ANNEXURE

12.1 Abbreviations

Tables

TABLES

TABLE 1 LIST OF CANCER IMMUNOTHERAPY DRUGS APPROVED (2016-APRIL 2019)
TABLE 2 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY DRUG TYPE, 2018–2025 ($BILLION)
TABLE 3 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY TREATMENT AREA, 2018–2025 ($BILLION)
TABLE 4 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE BY REGIONS, 2018–2025 ($BILLION)
TABLE 5 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY VENDOR RANKING, 2018
TABLE 6 OTHER PROMINENT VENDORS OF IMMUNOTHERAPY DRUGS MARKET
TABLE 7 ABBVIE INC.: OFFERINGS
TABLE 8 ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 9 AMGEN INC.: OFFERINGS
TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS
TABLE 11 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS
TABLE 12 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 13 BRISTOL-MYERS SQUIBB: OFFERINGS
TABLE 14 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
TABLE 15 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 16 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 17 MERCK & CO., INC.: PRODUCT OFFERINGS
TABLE 18 MERCK & CO., INC.: RECENT DEVELOPMENTS
TABLE 19 NOVARTIS AG: SNAPSHOT
TABLE 20 NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 21 GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 23 ASTRAZENECA PLC: SNAPSHOT
TABLE 24 ASTRAZENECA PLC: RECENT DEVELOPMENTS
TABLE 25 ELI LILLY AND COMPANY LTD: SNAPSHOT
TABLE 26 ELI LILLY AND COMPANY LTD: RECENT DEVELOPMENTS

CHARTS

CHART 1 GLOBAL PRESCRIPTION DRUG SALES, 2018–2025 ($BILLION)
CHART 2 GLOBAL OVER-THE-COUNTER DRUG MARKET REVENUE, 2018–2025, $BILLION
CHART 3 GLOBAL PHARMA SALES, BIOLOGICS V/S NON-BIOLOGICS (%)
CHART 4 GLOBAL PHARMACEUTICAL SALES BY REGION, 2018
CHART 5 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2017)
CHART 6 PHARMACEUTICAL DRUGS BY SALES, 2018 ($BILLION)
CHART 7 RESEARCH METHODOLOGY OF GLOBAL IMMUNOTHERAPY DRUGS MARKET
CHART 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET REVENUE, 2018–2025 ($BILLION)
CHART 9 SEGMENTATION OF GLOBAL IMMUNOTHERAPY DRUGS MARKET
CHART 10 PEST ANALYSIS OF GLOBAL IMMUNOTHERAPY DRUGS MARKET
CHART 11 PORTER 5 FORCES ON GLOBAL IMMUNOTHERAPY DRUGS MARKET
CHART 12 MARKET DYNAMICS – DRO ANALYSIS
CHART 13 DRO – IMPACT ANALYSIS OF GLOBAL IMMUNOTHERAPY DRUGS MARKET
CHART 14 KEY STAKEHOLDERS
CHART 15 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2018 AND 2025 ($BILLION)
CHART 16 GLOBAL MONOCLONAL ANTIBODY MARKET REVENUE, 2018–2025 ($BILLION)
CHART 17 GLOBAL VACCINE MARKET REVENUE, 2018–2025 ($BILLION)
CHART 18 GLOBAL NON-SPECIFIC IMMUNOTHERAPY MARKET REVENUE, 2018–2025 ($BILLION)
CHART 19 GLOBAL ADAPTIVE CELL THERAPY MARKET REVENUE, 2018–2025 ($BILLION)
CHART 20 GLOBAL OTHERS MARKET REVENUE, 2018–2025 ($BILLION)
CHART 21 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TREATMENT AREA SEGMENTATION, 2018 (%)
CHART 22 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TREATMENT AREA SEGMENTATION, 2025 (%)
CHART 23 GLOBAL CANCER MARKET REVENUE, 2018–2025 ($BILLION)
CHART 24 GLOBAL INFLAMMATORY AND AUTOIMMUNE DISEASE MARKET REVENUE, 2018–2025 ($BILLION)
CHART 25 GLOBAL INFECTIOUS DISEASE MARKET REVENUE, 2018–2025 ($BILLION)
CHART 26 GLOBAL OTHERS MARKET REVENUE, 2018–2025 ($BILLION)
CHART 27 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 (%)
CHART 28 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2025 (%)
CHART 29 IMMUNOTHERAPY DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($BILLION)
CHART 30 IMMUNOTHERAPY DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($BILLION)
CHART 31 IMMUNOTHERAPY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($BILLION)
CHART 32 IMMUNOTHERAPY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($BILLION)
CHART 33 ABBVIE INC.: OVERVIEW SNAPSHOT
CHART 34 ABBVIE INC.: GEOGRAPHIC REVENUE
CHART 35 ABBVIE INC.: SWOT ANALYSIS
CHART 36 AMGEN INC.: OVERVIEW SNAPSHOT
CHART 37 AMGEN INC.: GEOGRAPHIC REVENUE
CHART 38 AMGEN INC.: SWOT ANALYSIS
CHART 39 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
CHART 40 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS
CHART 41 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE
CHART 42 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
CHART 43 BRISTOL-MYERS SQUIBB: OVERVIEW SNAPSHOT
CHART 44 BRISTOL-MYERS SQUIBB: GEOGRAPHIC REVENUE
CHART 45 BRISTOL-MYERS SQUIBB: SWOT ANALYSIS
CHART 46 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 47 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 48 JOHNSON & JOHNSON: GEOGRAPHICAL REVENUE
CHART 49 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 50 MERCK & CO., INC.: OVERVIEW SNAPSHOT
CHART 51 MERCK & CO., INC.: BUSINESS UNITS
CHART 52 MERCK & CO., INC.: GEOGRAPHICAL REVENUE
CHART 53 MERCK & CO., INC.: SWOT ANALYSIS